Sino Biopharmaceutical Limited · HKEX:1177
Sino Biopharmaceutical — FY2024 Earnings Presentation
38 slides from Sino Biopharmaceutical's earnings presentation, Mar 20, 2025
Slide 1: Sino Biopharmaceutical Limited 2024 Results
“A J V hy oh BA See IRS a) SINO BIOPHARMACEUTICAL LIMITED (BERS: 1177.HK) 2025.3.20 Ex
Slide 2: iP at
iP at
Slide 3: 2024 results highlights
Weer 2024FIN A SULIT ES TK, PUTER EU ATR PROUT RAS (AB 1270) A10.2% 450.1% 433.5% 288.7 2023 2024 2023 2024 2023 2024 DEES yy pl $392 Non-HKFRSIaS FFD) 3E: 1) SiKBNon-HKFRSIAAHFA: AAABAEGLE—N, QNASTAREMABRMAADBEKR, HHERATFASAMBOENREELRBAASS a
Slide 4: Non-HKFRS profit reconciliation
$2i5)2Non-HKFRSIA Se HF (ARM 1270) 2024 2023 Re FRFRAANAAL SRA 35.0 23.3 +50.1% BALBEW START SADAs MARA 15.8 4.4 MAREADRS SAAS IBA RT RASH) 14 48 BTAPRARZARMADM RR UE ABA BT AS ALE) 13.9 1.0 FDCELAZ ARIMA SAMA), HA FORK BT RANT BALE) 0.0 -0.6 ARAMA EEF SOPRAD REIT ARIS UALEL) 0.4 0.2 BRAS ASM 2: ASB
Slide 5: Gross margin trend 2020-2024
SPF SACKS Hae, CARRE oN (AB 1270) a... HBRSHA ER) 2 £H1e 82.8% 81.0% nee 80.1% 78.1% rae eB ASR PREF EH 100001 EN RETEE, PASAY A psy b'5'4 2020 2021 2022 2023 2024 HRS RReS HEBe PRU ARAS
Slide 6: R&D investment and share of revenue
RAR AMMA, RRR MS BoA (ARib (272) RAS MERITS Wax TRAE AB (32) QU FTF mit AURA HA PUREE ESOT oR A 16.0% 16.8% aes 50.9 BWA IAT Sag, 11.1% FEAT AE bE 7 = 5 76% % a 59% BAH BOME, i—| SHB DRS CRED Est 2020 2021 2022 2023 2024 HBAS HBae BREE SE! 1) 20245 HRI APES LEA92.7%, (ARITA RE PES, HARIRI Bz ae
Slide 7: Expense ratios 2020-2024
HENS. GUSH EE, AMM RRp eA (ABib 1270) PECUER ASEH SG3ARA —e— SG&ARAS A17.0% 49.2% 47.3% 45.0% SUEA BRE, = AUBAAMSE ab Ee 42.2% 42.1% BARK AMSA, a 2020 2021 en ae 2024 PRPS AMS [= | #4y, HRSE HEE HEGH SHBBARMAAR CRMRKSAHLE, eal Vv 45% senueeare CO " 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 R
Slide 8: Cash flow and shareholder returns
REE BeENHUSI NR, KR EKHRAGR (ABib 1270) BEE IRBARHAB EK Rata ae A I Ee 193 HK39% = a 2ANZ, sasene 00% +neonex = | A : ~ « — xente = = : ™ | 2.0 19° 24 Bu 38 am ] 2022 2023 2024 2or2 2018 20142015, 2018 2017 20182018 2020 202K" gore 2028 2024 i TARAS EE RRBEMADE Fate hh ti Op , 10{Z \ EAR 2.5{Z. \ $e
Slide 9: 4K {0 0g iP at
4K {0 0g iP at
Slide 10: 2024 innovation milestones
DAT we wr meas, ARORA MAA REL WRATH Ath 20242 LAE ILE, —He | EIA. PFS RAT BRERA 1H, AAR —RIL_LBAIKRAS G12CiMiilA, AFIS BKRAS G12CR ES 4 /) ATE RMR RBBERREERE LRU, SMLAFROS 1 BAMEB a B0OG RASS AS HSE | RA Rar Beas SBIA® MRL AR eR TRAUB, AF AZALKHM PIAA AALK BATE BY BORE HAR EIS ‘NESE RABE REAY Far WR
Slide 11: Oncology segment revenue growth
QUFt Man 131521.9%, ARICA, (ABib 1270) 2355 Lemont RRS EE EME {ZO 2 : RO RBS] Sait RBA SoEH RK erent | BRS{tG-csF t Bethy FRARSEC hy rad Eso zAAeA = RIT : gu ASF y QB “i ay RY ait S ewer? aAZO | RZ N as cieaee eal TE S ae EAR 3E: 1) CUFF DAS MME MA fede A aR CUFT aa A CU A om ONE A Ste 41.8% 37.8% m
Slide 12: Oncology products revenue growth
UPA am H81521.9%, 24 Ri mR ME, (ABib 1270) QATE emo alene se, ele r ELST 1800S Bras 1) SAE ETE REDO QRARSRENR jee" B 12800 Rake - peor Ts see = 7M HHMRAM RR 3E: 1) CUFF DAS MME MA B08! 1 OUR EG 18008 BS 4 £ an a a PES X au BMAF ty, -ETRAUKRAS - ROS1SAtEAF/) G12CHDi A RRA TT ee REO HEPES RTO Bo REBAR
Slide 13: Other segment revenue growth
BHF 1K31%, SRS BAS, AtIABSIMIK A PROUT RAS (ARin 1270) FRIES MitAREAMHAGEMK PS loltite 13.1% $525 ah be 0+ BIZ haste 111 OFF RHE) \R AB kA =” 2023 2024 3E: 1) DUEARI AE ABT 13
Slide 14: Upcoming launches 2025-2027
CURRIER WA Te EERE, QT ELLE BSE TRH 60% J Ova @ rare @ 72 © maw OQ wiswe CUFF RA EE 50% 55% TQB2102 (HER232#TADC) TQB3909 (BCL-2i() #7) M701 (CD3/EpCAMZRi) TQB3616 (CDK2/4/6#n% 71) CPX102 (FRR) BIGfE: Zongertinib (HERZ) #4) TQH2722 (IL-4! TQ05105 (JAK/ROCK#D EI Fl) a PL-5 (i7vBaiR&) ed 89 QP001 (RBS
Slide 15: TQ05105 JAK/ROCK inhibitor
BBS tl ianit- A TQ05105 (JAK/ROCKH IF) SEKFIC, PRABAR TQ05105 iaRE 18 1188 Ea KBB Lae a4 RET JAK/ROCK HRB FY BitBaMies a a Less RLIINAI 2k First-in-class 8H Oop in A ASR SE Ib/IRBIAR Ste IMA + FBLA JAK (338) A ROCK (infFHEL) BIRR BORE + BR LPR, FREESE ai TQ051 0534 FF HEHE REMEMBER AI ES NITE A IMB)
Slide 16: TQC3721 PDE3/4 inhibitor for COPD
HSMM RHA bd TQC3721 (PDES/4i0sl fl) FH. SWANS, BRAB, BESERBIC wn Feavend 88 198 Ft] ct TQC3721 copp 520255 SIAR PDE3/4f0 6 FY copD 23% Best-in-class 77) TQC3721, ensifentrinestPDESHIPDE4RRARATA EER EL TQC372181FCOPDES lakBGER? PDE TQC3721 mgd NIG) aad NE) fn + IBY SEI aK (PDES) AONE (PDEA) HOE aI ic
Slide 17: QP001 analgesic
BBS el Mantt-BD WN QP001 (SSRN) BRAAMA, PHS RKRRMAMNSAIDENR, BIC aR QP001 AAR BSR LAR (COX-2ic FEM EF) FE SR ER RNSAENSA DER QP001 ATER EAR EE BA NAUK BHFABPHUERARSS SBFASPNELRSS + SORE RIASCU24/ NAR, PEER (2 q —B—RARGARENSA IDES aa Re aaa Pi Some an quae (N=128) tee (N=170) Hee 0-24 BSE 0-24h OgnF
Slide 18: CPX102 for RSV
BBS Ol Fanit-BD CPX102 (IFLA) StU MARSVATAWM, SERFIC, AHIR ceiver 188 18 1188 CPX102 BAL 3 PURI EU BL (RSV) MNBL (1L-29/FN-A1) aime BKB (SARS-CoV-2) Lali SRETHURAHRRSVATAM + MERA, RHR BLA ENHI1/100, CPX102AFFRSVERZ AL Nake LeRESSFRRE + ARSE LAND, RRR + HRENAANNER, | |\MRAELEES ABR ARES, THAT ‘(EFI S
Slide 19: 2024 launches: lung cancer therapies
20245¢ ErhEte= in A NRAFEB IH (PD-L1Sit) KARP BE, WME Re, NSCLCEBAGERIRABASCO ...c.. | RETO ALIMENT creas PD-18857 RFBE+ ARBRB SLO NARRATE ii . | PD-L1St O sez Pin tel eee oer} 2018 — - 1) =a X ial Ec Wto RBREURME FocusV BIGAFH, mPFS SRABAE MIRA Seat AmOsiy As HAAR ALBRAE Breet Ty 2019 # Hh. Ser FE
Slide 20: KRAS G12C inhibitor garsorasib
20245F Eh Stein WN WABE (KRAS G12CHB FA) Ft] AesE/) AAAS, He ASA Sco RATO Sas iS ve wee — > Si8tb MELO RE KRAS G12C HiFi! >I aR IWS GER GEAR) AREA R 2 + AEMS4EKRAS G12C "ABIKRAS G12CHREE (FA) STU AER REN MAME LS weeTSHA a 2 Rec RES (Garsorasib) SHRAMTBRRAEML i, 3 SMSO MIR IESS Garsorasib Fulzerasib
Slide 21: Breast cancer and HER2 epidemiology
20245F Eh Stein HRS EMRWARAR TRE, “HRA” EXAIRBHER2IEM FLARES HRIO “dune” Sa ets Oe xr) HAZE FMRWA UiPrse teat wknd FLERE \/ =pAtt ~15% = HER2PHtESRGPLERi =| HER2BASERRRAPLAR TE HER2+ r FURR SER — ARIE RARLRATACT RAM SEMAS POR ~20% HR+ MMe MDB | bE ~65% + ARERREUESR SS, ROR SRO + 2022%, SERLanena emi
Slide 22: TQB3616 CDK2/4/6 inhibitor
2025 brheier a A TQB3616 (CDK2/4/6HDiI Fl) Hak AHR+/HER2-FLBRREBIBICIT 1K cusnnpnae TQB3616 ene im # SF =n na 88 CDK2/4/6 HOF ait. —#GHR+/HER2-FLARRE i> 8 fit2025ERe te WRARAAB HR+/HER2-SLAREE BDA a Mmit2o2eeRR Lis + HICDK2, CDK4NMRAE AF AAI TARGA, FIRE SHACDKAEMZ) TQB3616-II1-01 Slr RTE) EE TQB3616
Slide 23: M701 CD3/EpCAM bispecific
202655 Eh Stein M701 (CD3/EpCAMIN4t) 387E RBS NS AGE TK AIIM TT AS wThe balun 18 1198 i RR M701 #5 EtHok (MA) CD3/EpCAMXNii MASsiat WILK (MPE) AERATES TEBE ET AR SFROHMREA, HHVialx 201287, SAT Ra M701 8928455 HL SES ABE KE M7018 97 ERR RBI ER) Breast ie IESE 701 SRsIR 6S) (N=43) (N=41) e-" Mm Nua /
Slide 24: Zongertinib HER2 inhibitor
20265% Eh Ete in BIG(E: Zongertinib (HERZ AA WAS GIF) LSHBK, BEBICTIE raving 1 18 TT) Fig. Zongerti nib > SHPHERDSea ps] an RS aD ceeiranes HER2Z4AFE/L BE EASY HERZ ESE SRARAE | HO BRR BER, ART. eEHEAYHER2 TKI Beamion LUNG-1 BA¥II1: Zongertinib 120mg QD (n=75) PREIS. PPHERZIESE ARATE RSS IMAI ER?) +
Slide 25: PL-5
20265 Eh Ete in PL-5 (RK) BRERA AY, MANBARMAM A SRI PL-5 Sueak SABRE RAM + CURT, PL-SRAARIRR HUE, SEA ARADO ARIA SIAR + EASTER a. BRERA GinH. ie. RS. CHAR + REITER (FART ARR MRS HHRELWR—-TEAR, ARBVRASH AUPERHSAR, WMP, PL-SiB URTAR RMSE, MARS : PRE, BRC CA. MAR + BRAS, FAL, SSHES + RSS, WHORAN, SRBAE
Slide 26: TQB2102 HER2 ADC
2027] Liner a A TQB2102 (HER2XI1ADC) 4XDS-8201BERSHKM, SiSMEMRAR - ARS TQB2102 watt Riven 18 1198 1188 He, HER23HHADC HEROES HER2BAtE (> —#%) IbRAIKS AR (BRIG a FLERE SSF Se ____any clei Herat wee Hearts =a \ APIVEOSRE — HERDIASR/BGA Co y IGM —HEROAEYE (RE. BR) Ho sn ° tH ° TQB210255DS-82014F MR RSE
Slide 27: Lanifibranor for MASH
2027F bhai i Lanifibranor (;ZPPARMaF!) BERR ERMASHAY, tear ptivind Wa 18 Lanifibranor aR RAREAT (HASH) JZPPAR Sahil) Lanifibranor-5 R25 Fs BITE CBI RE ABMASHEGIN = #ZPPAR THR-B FGF21 GLP-1498R S98 + BAERS PRIWESTHIGERINE, POPE THA rons ERR WMadrigal ak=ro 89bIo iD estes, FRIEBBIMASH2549 Lanifibranor
Slide 28: Expected data readouts in 2025 (oncology)
BASE Te 20255 Arh yaa REBENRSASK ©) —#ePD-L1BBMESE/| ARR DS-RY EEKZ5 IRA [ASCO] + BERRA |) AO ATRL SE AIERA HT UBB [ASCO] + SB) AaRC AE SMES IRE [ASCO] + HSA HE MIRA [ASCO] : EFLARIE IRA [ASCO] + —HiBb BRM MN [ESMO] + FHP INA [ASCO] Rowlett + — HA 7 iets MUA [ASCO] + BERRA MIRE [ASCO] RIBERA SN SHUR
Slide 29: Expected data readouts in 2025
BASE Te 20255 Arh fe5 TQB3616 (CDK2/4/6#) SIF) + —BHRH/HER2-FLERRE MIRE [ESMO] © CDK4/6ifit 259.8286 IIMA [ESMO/ SABCS] DAFF — AL2846 (AXL/METH SAS RESIN GIF) + SSC RUEFIRARSE IbHA [ESMO] — TQB3909 (BCL-2#0 #7) + SHERGAAIOTE As Ib/IRA [EHA] — TQB3454 (IDH1#0 85H) + PEARL A ay IMA [EHA] —— TQB3617 (B
Slide 30: AI-enabled drug discovery with Insilico
SAMBA! ERATE. HAL MASSER, LAAIRE & Insilico Insilico Medicine Medicine BLES {FE Au TE SEX #SSiTA SAR BSSA BAF RIBS AL, BHAGAT, HEF AMA E! REAR FE ZH CTeH = OQ Exae EE AlmAae e*xtalei RH ® 2021 RS ES RA SEKRMARA Ee tM, REAR Bears TUR aL DFA, HRA 1200H RTE SDE FRR Insilico 2022 ARBRI PEE Be 50RRTSSDH
Slide 31: ESG ratings
FRR RS MBIA, WRAP EH ,f yy ,f yy n) , Y, Ny Wa Global NG W copy V NY VW \4 W \¢ MSCI ESG RATINGS Top Score B © a MSCI ESG RATINGS S&P Global CSA Carbon Disclosure Project ERS — PRAT FEDS SERBI4% WOEHMRE “B” FORL-FER—D eH JERE HEA SABIAN ACE
Slide 32: Business development: license in and out
5TBDME Sih License in and out Sek OUR an drst Er SABIE
Slide 33: Appendix
iP at Bat
Slide 34: Oncology pipeline list
Be-WE OA RS aah a/R 1 TOB3616 = CDK2/4/6408) 2 TQ05105 JAKIROCK HEF EI AL2846 AXLMETES S28 iB 07 4 TOQB3454 IDH1HD 678) 5 TQB2102 - HER2ADC 6 701 CDS/EPCAMIRIA 7 TQB3473 SYKiM8IFA] 8 FHND9041 — EGFR#M/8) GR=At) 9 TQB3909 © BCL-2N457 10 LM-108 CORBET, 1" TQB2868 $APD-1/TGF-BILNAERA SA 12 TQB2930 HERG
Slide 35: Pipeline overview
BA EMARWAR HA eS kon a eo aro al ASH NDE Se BARRE Puen PREERR TBARS KES ae tt ALR BRBRPILEASZEF (IN ELAR AER SUITE RE PERFVEARE BARA AAR 2B FURR BRIE ESHER, MIHEARanAS RRBRB esd AEMRtA a HE TARE SAA He77 S| IPEOL SRA ITU aE ARE, PRABAAHO MS SEAR
Slide 36: Respiratory pipeline
HEAPS 1 TQH2722 0 IL4Raliii ARF EARL, MERA, SPETMERA 2 7acz731 — TSLP AH ADF LN, ERAS, (REET RR UES (COPD) es 3 yacs721 PDER AKAM) WF — SWHETESRYERH (COPD) Ee 4 Tacze38 «= STZ AGF RR, WIEN RTE EMR (COPD) | 5 TDI01 ROCK2#087) SF RIEBETMEAL (IPF), BH MITRE (GVHD) | cece eee eee] 6 cPx102 WELTER (IL-29
Slide 37: Other pipeline candidates
BE-IM| Bita ea fF! 7 PLS Bit. 2H = PRA 2 QP001 RS BVEIR (COX-2M0 87) SAR RAR 3 Naldemedine — Naly-SA SORAYA — Rn = RRS OIE 4 TRD205 ATARI SH WA RRIE . TRD303 SEAR (AR) =a ABR 6 YMP FRTALEREM (2HLRRR AT) TR ERR EMAVARHNA eS init eae ul NARA MOBFVila Ht ee rs RHR BASE . LES IMEM (EX) DPB ROAR. HR: BAB
Slide 38: Liver and metabolic pipeline
Baas SRS FERPA SE Lanifibranor J2PPAR MAb 2 TOA2225 FGF21iS 28 3 TO-AS334. TLR RAAT 4 TOQA3810 TLR-SRtA A 5 TOQA3605 HBV ZALES DAIAI (CAM) 6 TOQA3038 siRNA 7 CPX101 GIPRISHUGLP-AR BZA EMAVARGNA ATURE DEATH PRR BSNS PRMREA SORERINR ABBE SSRSEAMSM TTR BUSA AT PRLS Noone on Wak ADF WE Wa WOE WF RAE RAN
Sino Biopharmaceutical — FY2024 Earnings Presentation on 6ix